Disease · MONDO_0006497

cerebral palsy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cerebral palsy. Diseases, record MONDO_0006497. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006497

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cerebral palsy; Open Targets
Open Targets ID: MONDO_0006497; Open Targets
Other names: cerebral paralysis, infantile cerebral palsy; Open Targets
Disease Ontology: DOID:1969; Disease Ontology
MeSH: D002547; MeSH
NCI Thesaurus: C34460; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 58 drugs, from DailyMed; Open Targets

Drugs58

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BACLOFEN	CHEMBL701	Small molecule	Approval	DailyMed	6	4	4	Drugs and targets
CYCLOBENZAPRINE HYDROCHLORIDE	CHEMBL1200636	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DANTROLENE SODIUM	CHEMBL928	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DIAZEPAM	CHEMBL12	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
GLYCOPYRRONIUM TOSYLATE	CHEMBL3707243	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 3	ClinicalTrials.gov	16	16	12	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 3	ClinicalTrials.gov	11	11	1	Drugs and targets
LETIBOTULINUMTOXINA	CHEMBL3707322		Phase 3	ClinicalTrials.gov	4	4	0	Drugs and targets
INCOBOTULINUMTOXINA	CHEMBL2108035		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 58

See all 58 drugs

Targets152

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SNAP25	Synaptosomal-associated protein 25	5	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 3	https://conductscience.org/library/genes/6616	Drugs and targets
CHRM1	Muscarinic acetylcholine receptor	3	Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1128	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets
EPOR	Erythropoietin receptor	3	Erythropoietin receptor agonist	Phase 2	https://conductscience.org/library/genes/2057	Drugs and targets
GABRA1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2559	Drugs and targets

1 to 10 of 152

See all 152 targets

Trials45

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 26 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01893411	Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy	Phase 3	311	2017-05-12	Lower Limb Spasticity Due to Cerebral Palsy	INCOBOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT02106351	Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children	Phase 3	212	2019-12-24	Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov
NCT00491894	Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions	Phase 3	137	2012-07-09	Cerebral Palsy, Neurological Conditions, Mental Retardation, Sialorrhea	GLYCOPYRRONIUM BROMIDE	Its record names the disease	ClinicalTrials.gov
NCT01147653	A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy	Phase 2	63	2017-06-12	Cerebral Palsy, CP, Spastic Cerebral Palsy	AUTOLOGOUS CORD BLOOD	Its record names the disease	ClinicalTrials.gov
NCT00724594	Safety of N-acetylcysteine in Maternal Chorioamnionitis (NAC in Chorio)	Phase 1/2	46	2015-04-30	Chorioamnionitis, Brain Injury	ACETYLCYSTEINE	Its record names the disease	ClinicalTrials.gov
NCT01468350	Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy	Phase 1	35	2014-06-24	Cerebral Palsy (CP)	DALFAMPRIDINE	Its record names the disease	ClinicalTrials.gov
NCT01803464	Effect of Botox and Vibration on Bone in Children With Cerebral Palsy	Not applicable	29	2018-03-20	Cerebral Palsy, Muscle Spasticity	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov
NCT03623698	Nebulised Hypertonic Saline in Children and Young People With Neuromuscular Disease and Cerebral Palsy		24	2020-09-16	Neuromuscular Diseases	SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT03469999	Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy	Phase 3	12	2022-06-01	Cerebral Palsy	ABOBOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT03344952	Improvement on GMFCS Level of Patients With Cerebral Palsy Treated by Repeated Botulinum Toxin-A		503		Cerebral Palsy	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov

1 to 10 of 45

See all 45 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Autologous Umbilical Cord Blood Reinfusion vs Placebo: deaths from any cause	0 of 63	0 of 63	126	NCT01147653	Trial comparisons
Autologous Umbilical Cord Blood Reinfusion vs Placebo: serious adverse events	0 of 63	1 of 63	126	NCT01147653	Trial comparisons

Papers from its trials19

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34092664	RESULT	1	PubMed
25199575	RESULT	1	PubMed
25064164	RESULT	1	PubMed
24269277	RESULT	1	PubMed
20304327	RESULT	1	PubMed
19581264	RESULT	1	PubMed
38441919	DERIVED	1	PubMed
36281165	DERIVED	1	PubMed
36136523	DERIVED	1	PubMed
33206382	DERIVED	1	PubMed

1 to 10 of 19

See all 19 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006497

GET https://conductscience.org/api/diseases/v1/MONDO_0006497/drugs?page=2

API reference For AI assistants